AZ suffers Australian Crestor patent setback, could up M&A pressure
This article was originally published in Scrip
An unexpected court ruling from Australia invalidating patents on AstraZeneca's top drug, Crestor (rosuvastatin) will up pressure on the firm to dabble in further M&A, according to analysts, who have downgraded their core-EPS forecast for the firm. The company announced the news on 5 March.
You may also be interested in...
Recommendations from the Alliance for Regenerative Medicine aim to improve cross-border healthcare to ensure patients can access advanced therapies.
Patient access schemes have helped the Scottish Medicines Consortium recommend rare disease products, including Regeneron/Sanofi’s Libtayo for skin cancer.